Both drugs are in development for the treatment of obesity.8 While exenatide is a short acting GLP-1 analog, and, thus, does not provide substantial treatment benefits in comparison with liraglutide, semaglutide is a long acting GLP-1 analog with a once per week subcutaneous treatment (0.25 mg up to 1.0 mg). This evidence concerns the gene GCG and obesity disorder.